Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | CJC-1295 with DAC is a messenger that tells your brain to release more growth hormone. The "DAC" part acts like a super-glue, making the messenger stick around in your blood for a whole week instead of disappearing quickly. | Sermorelin is a gentle whisper to your brain, reminding it to produce growth hormone like it did when you were younger. It is very mild, making it a great starting point for safe, long-term anti-aging. |
Studied For | GH pulsatile release researchGH-axis anti-agingGrowth hormone deficiencyExtended GH secretionAnti-aging / longevity via GH axisMuscle growth via GH axisBody composition improvementFat reduction via GHSleep quality enhancementIGF-1 elevation researchRecovery and repair via GH axisBone density via GH stimulationCollagen synthesis via GH axisMetabolic rate increaseAdult GH deficiency modelsGH secretagogue researchcontinuous GH releasemuscle growthfat lossIGF-1 elevationrecovery | Pituitary GH-reserve diagnosticPediatric GH deficiency (historical)Adult GH-axis / anti-aging researchGH secretagogue researchIGF-1 elevationBody composition / lean massFat loss via GH axisBone density supportSleep quality via GHRecovery and repairGH deficiency modelsMetabolic rate improvementCollagen synthesis via GHAnti-aging longevity researchGH replacement alternativeanti-aginggrowth hormone secretagoguesleep improvementvitalitybody compositionpituitary health |
Research Areas | Performance & MuscleLongevityMetabolicJoint & Bone Support | Performance & MuscleLongevityMetabolicJoint & Bone Support |
Best Stacked With | ipamorelinghrp-6bac-water | ipamorelincjc-1295-no-dacghrp-2bac-water |
Overview | ||
Category | Muscle Growth & Performance | Muscle Growth & Performance |
Compound Class | Long-acting synthetic GHRH analog with Drug Affinity Complex (DAC) albumin-binding moiety | Synthetic 29-amino acid fragment of endogenous GHRH (GHRH 1-29-NH2) |
Molecular Target | GHRH receptor (GHRHR) on pituitary somatotrophs; sustained GH and IGF-1 elevation | GHRH receptor (GHRHR) on anterior pituitary somatotrophs; stimulates endogenous GH gene expression and release |
Aliases / AKA | CJC-1295 DACCJC 1295 with DACCJC1295 DACGHRH analog with DACCJC-1295 Drug Affinity ComplexDAC-GRF | GRF 1-29Sermorelin AcetateGerefGerelGRF(1-29)-NH2Growth hormone releasing factor 1-29 |
Parent Compound | Growth hormone releasing factor | Growth hormone releasing hormone |
Molecular Weight | ~3647 Da | ~3358 Da |
Amino Acid Sequence | tetrasubstituted GRF(1-29) + DAC | GHRH(1-29) amide |
CAS Number | 446262-90-4 | 86168-78-7 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | Not Listed | Not Listed |
PubMed Citations | Not Listed | Not Listed |
Clinical Trials | Not Listed | Not Listed |
Regulatory Status | Not FDA-approved; research chemical; WADA S2. | Was FDA-approved (withdrawn for commercial reasons); now compounded Rx; WADA S2. |
Evidence & Regulatory | ||
Half-Life | Not Listed | Not Listed |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | A 2006 human Phase 1/2 study showed single doses raised growth hormone for about 6 days and IGF-1 for 9 to 11 days. Limited evidence beyond early trials. | As the former drug Geref it increased growth velocity in deficient children and produced a reliable growth-hormone rise in stimulation testing. The branded product was withdrawn for commercial reasons, not safety. |
Side Effects Noted | Injection-site reactions, facial flushing, headache, water retention. Sustained non-pulsatile growth-hormone elevation raises a theoretical desensitization concern. | Injection-site reactions, flushing, headache, dizziness, nausea; rare hypersensitivity; antibody formation with chronic pediatric use. |
Warnings | Not approved; no chronic-use safety data; general growth-hormone-axis risks apply. WADA-prohibited. Research use only. | Requires a functional pituitary; response is blunted by obesity and high blood sugar. WADA-prohibited. Now dispensed as a compounded prescription in the US. |
Pharmacology | ||
Form | lyophilized | lyophilized acetate |
Diluent | bacteriostatic or sterile water | sterile diluent |
Storage Temp | cold, dark | cold, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Reactive DAC maleimide is moisture-sensitive. | Short-lived solution; use promptly. |
Reconstituted Shelf Life | 28 Days Refrigerated | 14 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
